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For most vitreoretinal specialists, the adoption of Ocriplasmin (OCP) into their practice 
remains controversial.  This might be due to the varying experience, positive and negative of 
individual practitioners.  In this issue, in a meta-analysis of over 400 patients from 18 series, 
Chatziralli et al showed that the rate of release of vitreomacular adhesion(VMA) was 46% 
but with a very wide range (from 0% to 71%) and wide standard deviation (21%) between 
series [1]. If you are one of the surgeons getting success rate of closer to 70%, you might be 
enthusiastic; alternatively, surgeons getting nearer 0% are likely to give up using OCP. There 
needs to be some explanation for this wide variation.  
Randomised controlled trials (RCT) give us a high level of evidence to guide us in our clinical 
practice.  Nevertheless, there is a need for real-life evidence. In the past, the results of some 
major RCTs simply could not be replicated. RCTs have strict inclusion and exclusion criteria 
and therefore limited external validity. In everyday practice, the selection of cases will be 
different; it could be broader or more restricted.  The mean rate of 46% in this meta-analysis 
is better than the landmark studies on OCP published in 2012 [2].  It is already known that 
phakic patients, female gender, absence of epiretinal membrane (ERM), and adhesions less 
1500 microns have higher rate of release of VMA [2,3].  Could the wide variation in efficacy in 
the 18 series reviewed by Chatziralli et al be simply a reflection of the differences in selection 
between series?  Indeed the VR interface in VMA is very variable not just by simplistic 
measures of extent. It is noteworthy that in the phase 3 trials the presence of ERM anywhere 
on the OCT was marked as present not merely at the point of VR attachment. Hyper-
reflectivity of the zone of VR interface was not scored and is a known factor in VR release [4]. 
Furthermore it is known that several diseases are associated with increased expression of 
adhesion molecules at the VR interface in the absence of discernible ERM explaining the 
reduced effect of OCP in patients with concomitant disease such as DMO [5].  
Besides selection, another possible reason for the variation in efficacy is the practicalities of 
the use of the drug in the clinic.  OCP is stored at -25oC in a pH of 3.1 which prevents serine 
de-protonation and limits the interaction of the drug with its substrates.  Hence the important 
recommendation that non buffered saline (pH 5.5) is used to reconstitute it, prolonging its action 
prior to injection into the [neutral pH] eye. Once defrosted and reconstituted, autolysis begins 
and unless the drug is used immediately, its effectiveness might be affected. Once injected it 
continues to autolyse and also interacts with other substrates in the vitreous cavity. This 
process is in turn limited by the action of naturally occurring serine protease inhibitors 
whose levels vary by disease [6]. To perform its desired action of VR release from the initial 
injection point it has to diffuse to the area of VR adhesion. With second order 
pharmacokinetics the distance and rate of the required diffusion to the VR attachment point 
are critical and it can be seen that a range of factors will affect the dose reaching the point of 
VR adhesion including the depth of injection and the structure of the vitreous.  This will not 
only affect the efficacy but also potentially the rate of off target side effects in the outer retina 
and zonules.    
Another justification for real-life studies is that more cases are needed to capture 
complications that occur infrequently or only with longer follow up.  The well-known case of 
cox-2 inhibitor Rofecoxib (Vioxx),  which was introduced in 1999 but was subsequently 
withdrawn in 2004, when it was confirmed that the drug was associated with 40% increase 
in cardiovascular event or death [7].  Chatziralli et al used the reported complications not 
just from the series included in the meta-analysis, but included all 194 papers which totalled 
874 eyes. This publication highlights the value of meta-analysis as some complications were 
not identified in the original MIVI-TRUST study.  These include changes to the ellipsoid zone, 
electroretinographic changes and enlargement of the macular hole in failed cases.  It is at 
least reassuring that most of the adverse effects reported have been reversible and transient 
although further study is needed.  
If OCP is to gain widespread acceptance, there has to be more to recommend it other than its 
safety profile.  There are other options in treating symptomatic VMT and macular holes. The 
drug is expensive.  Chatziralli et al included in their meta-analysis randomised controlled 
trials, case controlled studies and case series. The heterogeneity of the series, the lack of 
control groups and especially the differences in selection criteria make it difficult to compare.  
The authors seem to suggest that selection is the key.  In this regard, we would like to 
highlight a recent publication by Steel et al. By selecting using OCT parameters (the 
difference between base diameter and the minimal linear diameter) the group showed that it 
was possible to predict closure of macular hole with high confidence [8].  Ultimately, it is a 
higher degree of certainty of success that will persuade many surgeons.  
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